The combination antiretroviral therapy (cART) inhibit HIV replication effectively. However, synergy among these drugs has not been well considered. The dose of drugs used as monotherapy is the same as that used in combination therapy. Tenofovir+lamivudine+efavirenz is still the first line regimen of cART in developing countries. The side effects of these drugs are related to the concentration of drugs. Based on our previous data, we aim to evaluate whether reduce the dose of tenofovir and efavirenz could decreasing the incidence of the side effects while not scarifying their virological efficacy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
184
The Second Hospital of Nanjing
Nanjing, Jiangsu, China
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Yunnan AIDS care center
Kunming, Yunnan, China
Percentage of patients with HIV viral road < 50 copies/ml
calculate the percentage of patients who with HIV viral road \<50 copies/ml every month in two groups
Time frame: 48 weeks
Cell Differentiation 4 (CD4) T cell counts
Time frame: 48 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.